There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Sanjay Keswani Biography and Net Worth

EVP of Annexon

Dr. Keswani joined Annexon Biosciences as Chief Medical Officer in June 2019. He is an accomplished physician-scientist with broad R&D expertise in multiple therapeutic areas and is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Dr. Keswani has held senior executive positions in the pharmaceutical industry, including Roche, where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare diseases Research and Early Development. During his tenure at Roche, his group successfully advanced five molecules to Phase 3 development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He also held R&D leadership roles at Eli Lilly & Co. and Amgen, Inc. where he prosecuted the development of the now - approved CGRP antibodies for migraine prevention, Emgality and Aimovig.

Dr. Keswani completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins, where he cared for patients with diverse neurological diseases and ran a R01-funded Neuroimmunology research lab. He graduated in medicine at St. Bartholomew’s Hospital (England’s oldest medical school founded in 1123). In addition, he holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).

What is Sanjay Keswani's net worth?: The estimated net worth of Sanjay Keswani is at least $24,449.40 as of March 24th, 2021. Dr. Keswani owns 3,995 shares of Annexon stock worth more than $24,449 as of November 17th. This net worth approximation does not reflect any other investments that Dr. Keswani may own. Learn More about Sanjay Keswani's net worth.
How do I contact Sanjay Keswani?: The corporate mailing address for Dr. Keswani and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Sanjay Keswani's contact information.
Has Sanjay Keswani been buying or selling shares of Annexon?: Sanjay Keswani has not been actively trading shares of Annexon over the course of the past ninety days. Most recently, Sanjay Keswani sold 3,995 shares of the business's stock in a transaction on Wednesday, March 24th. The shares were sold at an average price of $30.17, for a transaction totalling $120,529.15. Following the completion of the sale, the executive vice president now directly owns 3,995 shares of the company's stock, valued at $120,529.15. Learn More on Sanjay Keswani's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 5 times. They purchased a total of 362,800 shares worth more than $1,080,928.00. During the last twelve months, insiders at the sold shares 10 times. They sold a total of 52,736 shares worth more than $291,579.19. The most recent insider tranaction occured on October, 15th when EVP Ted Yednock sold 5,408 shares worth more than $40,073.28. Insiders at Annexon own 12.7% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 10/15/2024.

Sanjay Keswani Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/24/2021	Sell	3,995	$30.17	$120,529.15	3,995

Sanjay Keswani Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $6.12

$6.02

$6.49

50 Day Range

MA: $6.91

$5.92

$7.63

2 Week Range

Now: $6.12

$2.27

$8.40

Volume

1,917,213 shs

Average Volume

1,168,588 shs

Market Capitalization

$646.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23